Eli Lilly and Company (NYSE:LLY) Shares Purchased by Hantz Financial Services Inc.

Hantz Financial Services Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 0.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 17,961 shares of the company’s stock after acquiring an additional 155 shares during the quarter. Hantz Financial Services Inc.’s holdings in Eli Lilly and Company were worth $15,912,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. LRI Investments LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at $81,000. Objective Capital Management LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at $239,000. Westwood Holdings Group Inc. lifted its holdings in Eli Lilly and Company by 5.4% in the first quarter. Westwood Holdings Group Inc. now owns 3,839 shares of the company’s stock valued at $2,987,000 after acquiring an additional 196 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 13.6% in the first quarter. EverSource Wealth Advisors LLC now owns 3,509 shares of the company’s stock valued at $2,741,000 after acquiring an additional 420 shares during the period. Finally, American Trust raised its stake in shares of Eli Lilly and Company by 0.6% during the 1st quarter. American Trust now owns 2,493 shares of the company’s stock worth $1,939,000 after buying an additional 14 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

LLY has been the subject of several research reports. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Wolfe Research initiated coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target for the company. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Finally, Guggenheim lifted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Stock Down 0.1 %

LLY opened at $788.19 on Friday. The business has a 50-day moving average of $854.42 and a two-hundred day moving average of $869.27. The stock has a market capitalization of $748.24 billion, a price-to-earnings ratio of 85.21, a price-to-earnings-growth ratio of 2.99 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s revenue was up 20.4% on a year-over-year basis. During the same period last year, the firm posted $0.10 earnings per share. On average, research analysts expect that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.66%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.